PYC
PYC Therapeutics Ltd
Biotechnology
·
Healthcare
14
comments
2
fund managers
3
past 90 days
About PYC Therapeutics Ltd
PYC Therapeutics Ltd. is an Australian drug-development company headquartered in Nedlands. Founded in 2001 by Richmond Miles Hopkins and Paul Michael Watt, the company specializes in RNA therapeutics designed to address unmet medical needs. PYC Therapeutics utilizes its proprietary cell-penetrating Phylomers platform to develop intracellular biological therapeutics, including a portfolio of preclinical oncology payloads. The firm focuses on advancing next-generation RNA therapies through its specialized delivery technology.
Commentary Volume
14
Comments
2
Fund managers
3
Past 90 days
SOURCE
ACTION
COMMENT PREVIEW
FUND MANAGER
DATE
The fund manager initiated a position in PYC Therapeutics (PYC), following a deep dive into the biotech sector, noting PYC emerged as a key contributor in April with its focus on developing precision medicines for severe diseases lacking treatment options. The manager highlights three drug candidates poised for human safety and efficacy readouts within the next 18 months addressing critical unmet needs in Retinitis Pigmentosa, Polycystic Kidney Disease, and Autosomal Dominant Optic Atrophy.
Source: Salter Brothers Monthly Report · Published: 30 Apr 2024 · Price: ~$0.96
30 Apr 2024
SB
Salter Brothers
Initiated
Monthly Report
The fund manager initiated a position in PYC Therapeutics (PYC), noting the company announced significant progress in its drug development pipeline in June including positive results for its fourth drug candidate targeting Phelan-McDermid Syndrome and promising outcomes in clinical trials for Retinitis Pigmentosa type 11. The manager describes PYC as an RNA therapeutics drug development company with a pipeline of first-in-class drug candidates targeting significant unmet medical needs.
Source: Salter Brothers Monthly Report · Published: 30 Jun 2024 · Price: ~$1.19
30 Jun 2024
SB
Salter Brothers
The fund manager initiated a position in…
Initiated
Monthly Report
§ Important Notice
The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Commentary
Sector
Healthcare
Market cap
$1B
Fund managers
2 managers
First covered
30 Apr 2024
Last updated
30 Apr 2026
Company Details
Related Themes
ic
Ipsum Capital
6 comments
ic
Amet Funds
4 comments
ic
Dolor
3 comments
Top Investors Covering MIN
§ Reminder
The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Frequently asked questions about PYC Therapeutics Ltd (ASX:PYC)
Frequently asked questions
Who is investing in PYC Therapeutics Ltd (ASX:PYC)?
Fund managers including Salter Brothers and Firetrail Investments have invested in PYC Therapeutics Ltd (ASX:PYC).
What is the short interest in PYC Therapeutics Ltd (ASX:PYC)?
The short interest in PYC Therapeutics Ltd (ASX:PYC) is 0.35% which makes it the 316th most shorted stock on the ASX. Of the 583.3M shares that PYC Therapeutics Ltd has on issue, 2.1M have been sold short.
What does PYC Therapeutics Ltd (ASX:PYC) do?
PYC Therapeutics Ltd. is an Australian drug-development company headquartered in Nedlands. Founded in 2001 by Richmond Miles Hopkins and Paul Michael Watt, the company specializes in RNA therapeutics designed to address unmet medical needs. PYC Therapeutics utilizes its proprietary cell-penetrating Phylomers platform to develop intracellular biological therapeutics, including a portfolio of preclinical oncology payloads. The firm focuses on advancing next-generation RNA therapies through its specialized delivery technology.
The fund manager initiated a position in…